Ondansetron controlled-release - RedHill Biopharma

Drug Profile

Ondansetron controlled-release - RedHill Biopharma

Alternative Names: BEKINDA; Bimodal release ondansetron; CDT-ondansetron; Once-daily ondansetron; RHB-102

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator SCOLR Pharma
  • Developer RedHill Biopharma
  • Class Antiemetics; Antipsychotics; Carbazoles; Imidazoles; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Phase III Nausea and vomiting
  • Phase II Irritable bowel syndrome

Most Recent Events

  • 14 Jun 2017 Topline efficacy and adverse events data from the phase III GUARD trial in Nausea and vomiting (in patients with acute gastroenteritis or gastritis) released by RedHill Biopharma
  • 24 Apr 2017 RedHill Biopharma completes enrolment in its phase II trial for Irritable bowel syndrome in USA (PO)
  • 18 Apr 2017 RedHill BioPharma receives patent allowance for ondansetrone controlled release in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top